Comparison of efficacy and safety of topical tacrolimus vs. narrowband ultraviolet B for moderate-severe atopic eczema

Abstract

Objective To compare the efficacy and safety of topical tacrolimus with narrowband ultraviolet B for moderate-severe atopic eczema.   Methods 60 subjects, equally divided into Group A and B with the former treated with topical tacrolimus and the latter received narrowband ultraviolet B (NB UVB). These patients were followed up at 2, 4, 6, 8 and 12th weeks. Efficacy and side effects of the given treatment were recorded at each visit.   Results 90% of patients receiving NB UVB showed ≥50% SCORAD reduction as compared to 50% of cases applying tacrolimus. Fewer patients (60%) on NB UVB had side effects as compared to 66% of tacrolimus patients.   Conclusion NB UVB is a more effective and safer therapy than topical tacrolimus in moderate-severe atopic dermatitis in our patients.